Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections

Juan José Castón; Álvaro De La Torre; Isabel Ruiz-Camps; María Luisa Sorlí; Vicente Torres; Julián Torre-Cisneros

doi:10.1128/AAC.02136-16

Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections

Juan José Castón, Álvaro De La Torre, Isabel Ruiz-Camps, María Luisa Sorlí, Vicente Torres, Julián Torre-Cisneros

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

36 Citations (Scopus)

Abstract

© 2017 American Society for Microbiology. All Rights Reserved. Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.

Original language	English
Article number	e02136
Journal	Antimicrobial Agents and Chemotherapy
Volume	61
Issue number	3
DOIs	https://doi.org/10.1128/AAC.02136-16
Publication status	Published - 1 Mar 2017

Keywords

Ceftolozane-tazobactam
Pseudomonas aeruginosa
Salvage therapy

Access to Document

10.1128/AAC.02136-16

Fingerprint Dive into the research topics of 'Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections'. Together they form a unique fingerprint.

Cite this

@article{e5018c2e03734835b4166c8eb199fe46,

title = "Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections",

abstract = "{\textcopyright} 2017 American Society for Microbiology. All Rights Reserved. Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.",

keywords = "Ceftolozane-tazobactam, Pseudomonas aeruginosa, Salvage therapy",

author = "Cast{\'o}n, {Juan Jos{\'e}} and {De La Torre}, {\'A}lvaro and Isabel Ruiz-Camps and Sorl{\'i}, {Mar{\'i}a Luisa} and Vicente Torres and Juli{\'a}n Torre-Cisneros",

year = "2017",

month = mar,

day = "1",

doi = "10.1128/AAC.02136-16",

language = "English",

volume = "61",

number = "3",

}

Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. / Castón, Juan José; De La Torre, Álvaro; Ruiz-Camps, Isabel; Sorlí, María Luisa; Torres, Vicente; Torre-Cisneros, Julián.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 3, e02136, 01.03.2017.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections

AU - Castón, Juan José

AU - De La Torre, Álvaro

AU - Ruiz-Camps, Isabel

AU - Sorlí, María Luisa

AU - Torres, Vicente

AU - Torre-Cisneros, Julián

PY - 2017/3/1

Y1 - 2017/3/1

N2 - © 2017 American Society for Microbiology. All Rights Reserved. Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.

AB - © 2017 American Society for Microbiology. All Rights Reserved. Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.

KW - Ceftolozane-tazobactam

KW - Pseudomonas aeruginosa

KW - Salvage therapy

U2 - 10.1128/AAC.02136-16

DO - 10.1128/AAC.02136-16

M3 - Article

VL - 61

IS - 3

M1 - e02136

ER -